EP0429585A4 - Cytochalasin compositions and therapeutic methods - Google Patents

Cytochalasin compositions and therapeutic methods

Info

Publication number
EP0429585A4
EP0429585A4 EP19900907829 EP90907829A EP0429585A4 EP 0429585 A4 EP0429585 A4 EP 0429585A4 EP 19900907829 EP19900907829 EP 19900907829 EP 90907829 A EP90907829 A EP 90907829A EP 0429585 A4 EP0429585 A4 EP 0429585A4
Authority
EP
European Patent Office
Prior art keywords
cytochalasin
compositions
therapeutic methods
therapeutic
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900907829
Other languages
English (en)
Other versions
EP0429585A1 (fr
Inventor
Thomas P. Fondy
Dennis Bogyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syracuse University
Original Assignee
Syracuse University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syracuse University filed Critical Syracuse University
Publication of EP0429585A1 publication Critical patent/EP0429585A1/fr
Publication of EP0429585A4 publication Critical patent/EP0429585A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP19900907829 1989-04-28 1990-04-27 Cytochalasin compositions and therapeutic methods Withdrawn EP0429585A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34501089A 1989-04-28 1989-04-28
US345010 1989-04-28

Publications (2)

Publication Number Publication Date
EP0429585A1 EP0429585A1 (fr) 1991-06-05
EP0429585A4 true EP0429585A4 (en) 1992-03-25

Family

ID=23353087

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900907829 Withdrawn EP0429585A4 (en) 1989-04-28 1990-04-27 Cytochalasin compositions and therapeutic methods

Country Status (4)

Country Link
EP (1) EP0429585A4 (fr)
JP (1) JPH03505744A (fr)
CA (1) CA2031520A1 (fr)
WO (1) WO1990013293A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250563A (en) * 1991-09-25 1993-10-05 Merck & Co., Inc. Inhibitors of HIV protease
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0616530A1 (fr) * 1991-12-09 1994-09-28 Usher, Thomas Clemens Utilisation de cytochalasines pour inhiber la replication virale
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5342926A (en) * 1993-06-08 1994-08-30 The Regents Of The University Of California Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport
EP1512398A1 (fr) 1997-03-31 2005-03-09 Boston Scientific Limited Stent intravasculaire avec des inhibiteurs cytosquelettiques pour la prévention de la restenose
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
ATE442128T1 (de) * 1997-12-04 2009-09-15 Yissum Res Dev Co Kombinierte chemo-immunotherapie mit liposomalen arzneistoffen und cytokinen
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
JP5397692B2 (ja) * 2007-11-28 2014-01-22 国立大学法人名古屋大学 悪性黒色腫抗原の発現上昇剤及びその用途
US11007176B2 (en) 2019-02-19 2021-05-18 Tzu Chi University Use of actin depolymerizing agents for the treatment of anxiety disorders
CN110563634B (zh) * 2019-09-09 2020-12-08 湖南省中医药研究院 吲哚细胞松弛素类化合物及其制备方法和应用
CN111249445B (zh) * 2020-02-27 2022-11-15 广东医科大学 一种细胞松弛素h软胶囊及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291151A1 (fr) * 1984-08-13 1988-11-17 Harry H. Leveen Compositions contenant des dérivés de phlorizine pour le traitement du cancer
EP0297946A2 (fr) * 1987-06-19 1989-01-04 Syracuse University Méthodes de purification de cytochalasine et ses compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0291151A1 (fr) * 1984-08-13 1988-11-17 Harry H. Leveen Compositions contenant des dérivés de phlorizine pour le traitement du cancer
EP0297946A2 (fr) * 1987-06-19 1989-01-04 Syracuse University Méthodes de purification de cytochalasine et ses compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 32, no. 6, 1991, pages 400-405, Springer Verlag; D. BOGYO et al.: "Cytochalasin-B-induced immunosuppression of murine allogeneic anti-tumor response and the effect of recombinant human interleukin-2" *
CELLULAR IMMUNOLOGY, vol. 69, 1982, pages 235-247, Academic Press, Inc.; S. STOSIC-GRUJICIC et al.: "Modulation of interleukin 1 production by activated macrophages: in vitro action of hydrocortisone, colchicine and cytochalasin B1" *
See also references of WO9013293A1 *

Also Published As

Publication number Publication date
WO1990013293A1 (fr) 1990-11-15
JPH03505744A (ja) 1991-12-12
EP0429585A1 (fr) 1991-06-05
CA2031520A1 (fr) 1990-10-29

Similar Documents

Publication Publication Date Title
GB9005336D0 (en) Cleaning compositions and methods
ZA902231B (en) Composition and use
AP9000234A0 (en) Therapeutic nucleocides
GB2238187B (en) Connectors and parts
GB8907410D0 (en) Paving breakers and supports therefor
GB8917470D0 (en) Composition and method
EP0435554A3 (en) Rubber compositions and preparation thereof
SG42865A1 (en) Therapeutic compositions and methods
EP0502080A4 (en) Anti-inflammatory compositions and methods
EP0429585A4 (en) Cytochalasin compositions and therapeutic methods
NZ233011A (en) Thieno-triazole-diazepine and pharmaceutical compositions
LTIP1406A (en) Edulcorant and its preparation process
EP0416363A3 (en) Modified polyarylenesulfides
EP0416108A4 (en) Nutritious composition
GB9016171D0 (en) Fungicidal compositions and method
GB2230529B (en) "simulated colored granite and process"
GR890100860A (en) Composition based on trimebutyne and preparation process
EP0411415A3 (en) Polyethercarboxylic esters and their preparation
IL94030A0 (en) Dioxydiphthalic anhydride and its preparation
HU9200248D0 (en) Degerminative methods
GR900300184T1 (en) Preparation and its use
GB8917397D0 (en) Two-part bodice
EP0408495A3 (en) Substituted tetrachalcogen fulvalenes and process for their preparation
GB8901584D0 (en) Sparkler
IE891418L (en) Fluoroavermectins and fluoromilbemycins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19910506

A4 Supplementary search report drawn up and despatched

Effective date: 19920206

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920422